E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prevention of Rotavirus Gastroenteritis Caused by Serotypes G1, G2, G3, G4, and G-Serotypes Associated With P1A [8] (e.g., G9) in Infants |
|
E.1.1.1 | Medical condition in easily understood language |
Diarrhea and vomiting caused by the rotavirus germ in infants. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10039232 |
E.1.2 | Term | Rotavirus gastroenteritis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate that the immunogenicity of DTP-IPV in the concomitant administration group (Group 1) is non-inferior to that in the staggered administration group (Group 2). |
|
E.2.2 | Secondary objectives of the trial |
(1) To evaluate the safety and general tolerability of the concomitant administration of DTP-IPV and V260.
(2) To summarize the GMTs (Geometric mean titers) of DTP-IPV descriptively for each antibody in Japanese infants both for the concomitant administration group (Group 1) and the staggered administration group (Group 2).
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Merck will conduct Future Biomedical Research on DNA (buccal swabs) specimens collected during this clinical trial. Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol (as part of the main trial) and will only be conducted on specimens from appropriately consented subjects. The objective of collecting specimens for Future Biomedical Research is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer, more effective drugs, and/or to ensure that subjects receive the correct dose of the correct drug at the correct time. |
|
E.3 | Principal inclusion criteria |
1. Healthy Japanese infants.
2. Age 6 weeks through less than 11 weeks (≥42 days to ≤76 days from Date of Birth) at Visit 1.
3. Parent/legal guardian understands the study procedures, alternative treatments available, and risks involved with the study, and voluntarily agree to participate by giving written informed consent. The parent/guardian may also provide consent for Future Biomedical Research. However, the patient may participate in the main trial without participating in the Future Biomedical Research.
|
|
E.4 | Principal exclusion criteria |
At Visit 1, subjects should not have any exclusion criteria. As for exclusion criteria with an asterisk [*], if the subject meets this criterion at any visit, the visit may be resche duled when the criterion no longer applies.
1. * Subjects who are clearly feverish, axillary temperature ≥37.5ºC at the time of vaccination.
2. * Subjects who clearly have acute active disease.
3. Subjects with a history or a risk of hypersensitivity and/or anaphylaxis to any of the product ingredients in V260 and/or DTP-IPV.
4. Subjects with gastrointestinal disorder (active gastrointestinal disease, chronic diarrhea, prior rotavirus gastroenteritis, abdominal surgery), growth retardation, or failure to thrive.
5. Subject with history of intussusception.
6. Subject with untreated congenital gastrointestinal disorder (such as Meckel diverticulum) that may increase the onset of intussusceptions.
7. Known or suspected impairment of immunological function, including severe combined immunodeficiency (SCID).
8. Subjects who have underlying diseases such as cardiovascular, renal, liver, or blood diseases.
9. Subjects with a history of convulsion.
10. Subjects undergoing immunosuppressive therapy (including high -dose systemic corticosteroids [≧2mg/kg/day of prednisolone or equivalent] ) or subjects living with a close relative with congenital immune deficiency. Note: Subject using nonsystemic corticosteroids (e.g., topical, ophthalmic, or inhaled) will be eligible for vaccination.
11. Subjects who have received a blood transfusion or blood products, including immunoglobulin.
12. Prior vaccination of rotavirus vaccine and/or DTP-IPV vaccine (including any component of DTP-IPV vaccine).
13. Subjects who have not passed 28 days after live vaccine administration or 7 days after receiving inactivated vaccine.
14. Participation in another interventional study within 14 days prior to the first study vaccination or expected anytime during the study.
15. Subjects who plan to permanently relocate from the area prior to the completion of the study or to leave for an extended period (visiting grandmother’s home) of time when study visits would be scheduled.
16. Subjects who are at high risk of tuberculosis exposure (e.g., subjects living in a household with a person who is under TB treatment or a person with suspected infection with the tubercle bacillus).
17. * Inability to obtain blood specimen at randomization visit. Note: Re-schedule visit so that baseline specimen may be obtained prior to the first vaccination
18. Subjects whom the physician considers unsuitable to vaccinate.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Immunogenicity Endpoints
The endpoint is the percentage of subjects who achieve a serologic response as defined in the protocol for diphtheria toxin, tetanus toxin, pertussis toxin, pertussis FHA and Polio virus type 1/2/3 at 4-6 weeks after the 3rd dose of DTP-IPV elicited by vaccination.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
4-6 weeks after the 3rd dose of DTP-IPV |
|
E.5.2 | Secondary end point(s) |
Immunogenicity Endpoints
The secondary immunogenicity endpoints for evaluating antibody responses to DTP-IPV are geometric mean titers (GMTs) of immunogenicity measurements (antibody levels) baseline (pre-vaccination) and at 4-6 weeks after the 3rd dose.
Safety Endpoints
For the evaluation of safety of V260 when administered concomitantly with DTP-IPV, all subjects in the study will be followed for any clinical adverse experiences occurring within 14 days of all study visits. In addition, vaccine-related serious adverse experiences, deaths, and cases of intussusception (ECI) are to be reported at any time during the study.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Immunogenicity Endpoints
Baseline and at 4-6 weeks after the 3rd dose.
Safety Endpoints
14 days following any scheduled visit (visits 1-6) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Experimental (Staggered group) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial months | 9 |